PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications.

Zhifei Xu,Zizheng Gao,Huangxi Fu,Yan Zeng,Ying Jin,Bo Xu,Yuanteng Zhang,Zezheng Pan,Xueqin Chen,Xiaochen Zhang,Xiaohong Wang,Hao Yan,Xiaochun Yang,Bo Yang,Qiaojun He,Peihua Luo

Cardiovascular research（2023）

引用 3|浏览25

暂无评分

摘要

We identified PTX3 as a potential biomarker and target for the treatment of trastuzumab-induced cardiac complications and demonstrated that lapatinib can prevent cardiac dysfunction caused by trastuzumab by blocking EFGR/STAT3-mediated PTX3 release from VECs, which provided a mechanistic rationale for the combined application of lapatinib and trastuzumab in cancer.

查看译文

关键词

Cardiac Complications,Lapatinib,PTX3,Trastuzumab,Vascular Endothelial Cells

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要